[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sclerosis-multiple\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sclerosis-multiple":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100354845","french-registry-for-monitoring-pregnancies-for-multiple-sclerosis-100354845",false,"NCT03900221","French Registry for Monitoring Pregnancies for Multiple Sclerosis","French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort","RESPONSE","Inclusion Criteria:\n\n* All groups of patients eligible to participate to the Observatoire Français de la Sclérose en Plaque (OFSEP), including :\n* Definite Multiple sclerosis (MS) according to McDonald criteria\n* Whatever the clinical course (single attack MS, relapsing-remitting MS, secondary progressive MS, primary progressive MS)\n* Radiologically Isolated Syndromes (RIS) (will be validated by the RIS expert group)\n* Clinically Isolated Syndromes (CIS)\n* Neuromyelitis optica (NMO) and NMO spectrum disorders (will be validated by the \"Neuro-optico-myélite aiguë de Devic et des syndromes neurologiques apparentés\" (NOMADMUS) expert group)\n* No age limit (patients under the age of 18 might be included, provided informed consent is obtained from the parents)\n* Ongoing pregnancy: there will be no limit in the gestational age at inclusion. Women can be included at any time before delivery, but the gestational age at inclusion will be recorded and introduced in the analyses whenever pertinent. However, neurologists and patients will be encouraged to start the study as soon as pregnancy is diagnosed.\n* Able to give informed consent\n* Able to read and\u002For understand French\n\nExclusion Criteria:\n\n* None","ALL",{"count":19,"type":20},1500,"ESTIMATED","7 Years","OBSERVATIONAL","The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has radically changed and many patients have been able to fulfill their desire of motherhood. However, there are still some challenges for the neurologist, who has to face old unanswered questions or new issues, regarding the use of disease modifying drugs (DMDs) in this period of life, effects on the short and long term outcome of the mother (in terms of relapses and disability) and the child, role of breast-feeding and locoregional analgesia.\n\nTo set up a national prospective pregnancy registry for patients with MS, nested within the Observatoire Français de la Sclérose en Plaque (OFSEP) cohort, owing to a better knowledge of interactions between MS and pregnancy-related issues (pregnancy itself, locoregional analgesia, breastfeeding, impact of using or stopping DMDs on women\u002Fchildren…)",[25,26,27,28],"Sclerosis, Multiple","Neuromyelitis Optica Spectrum Disorder","Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders","Pregnancy Abnormal",[30,31,32,33,34],"Multiple sclerosis","pregnancy","disease modifying drugs","breastfeeding","loco-regional analgesia","RECRUITING","2025-12-30",{"date":38,"type":39},"2026-01-05","ACTUAL",{"date":41,"type":39},"2019-08-12",{"date":43,"type":20},"2036-08-12",{"name":45,"class":46},"Hospices Civils de Lyon","OTHER",48,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":5},"100524738","the-dancerex-proof-of-concept-study-for-chronic-neurological-disorders-100524738","NCT06112639","The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders","DANCE REhabilitation Experience (DANCEREX-DTx): Protocol for a Randomized Controlled Trial on Effectiveness of Digital Therapeutics in Chronic Neurological Disabilities","DANCEREX-DTx","Inclusion Criteria:\n\n1. age between 18 and 85 years (adult and older adult);\n2. education equal to or more than five years\n3. agreement to participate with the signature of the informed consent form;\n4. clinical diagnosis of Multiple Sclerosis (MS) according to the 2017 revised criteria of MC Donald - Expanded Disability Status Scale (EDSS) score equal or less than 4.5, R-R disease course, freedom from relapses, and steroid treatment for at least one month, OR clinical diagnosis of pre-Mild Cognitive Impairment - MCI (Subjective Memory Complaints and\u002For Subjective Cognitive Complaints)\u002FMCI at risk of Alzheimer's Disease with the Clinical Dementia Rating (CDR) scale equal or less than 0.5\n5. Normal score to a screening test for cognitive impairment (Montreal Cognitive Assessment test - MoCA test \\> 15.5 Santangelo et al., 2015)\n\nExclusion Criteria:\n\n1. presence of comorbidities that prevent patients from undertaking a safe home program (e.g., balance problems, history of falls in the past 6 months, use of assistive devices for deambulation)\n2. presence of overt hearing\u002Fvisual impairment\n3. for the MCI group, the absence of a caregiver\u002Fstudy partner able to support the participant;\n4. no living in one's own home;\n5. for the MS group, score in cerebellum function at EDSS greater than 3","18 Years","85 Years",{"count":59,"type":20},192,"INTERVENTIONAL",[62],"NA","The goal of this clinical trial is to test a new digital therapeutic solution which combines a holistic, multidimensional rehabilitation program based on dance and music with an innovative motivational system (DANCEREX-DTx) in Chronic Neurological Disorders (Multiple Sclerosis and pre-Mild Cognitive Impairment - MCI\u002F MCI at risk of Alzheimer's Disease). The main questions it aims to answer are 1\\] efficacy of the digital therapeutic solution in terms of adherence, clinical\u002Ffunctional measures, quality of life and surrogate measures; 2\\] usability and acceptability of the system.\n\nParticipants will be randomized (with an allocation ratio of 2:2:1) into the experimental group (DANCEREX - 24 sessions of multidimensional dance-based program integrated with an innovative motivational system), active comparator group (24 sessions of multidimensional dance-based program) and placebo group (24 sessions of educational program). Researchers will compare the experimental group to the other two groups to see if a digital therapeutic solution integrating a multidimensional dance-based program and motivational system is effective in increasing adherence to rehabilitation treatment.",[25,65,66],"Neurocognitive Impairment, Mild","Neurocognitive Dysfunction",[68,69,70,71,72,73,74,75],"rehabilitation","multiple sclerosis","dementia","digital therapeutics","neurocognitive dysfunction","MRI","neuroinflammation","telerehabilitation","2025-01-09",{"date":78,"type":39},"2025-01-10",{"date":80,"type":39},"2024-01-31",{"date":82,"type":20},"2025-10-31",{"name":84,"class":46},"Fondazione Don Carlo Gnocchi Onlus",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":17,"minAge":56,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":60,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100331862","application-of-ihmt-mri-in-multiple-sclerosis-100331862","NCT03600779","Application of ihMT MRI in Multiple Sclerosis","Application of the Inhomogeneous Magnetisation Transfer MRI (ihMT) Technique, a New Myelin-specific MRI Technique, in Multiple Sclerosis","ihMTMS","Inclusion Criteria:\n\n* For Patients and Controls :\n\n  * Adult patient, male and female, age 18 to 45\n  * Patient affiliated with health insurance coverage,\n  * Patient who signed a free and informed consent after receiving detailed, understandable and honest information,\n* For patients only :\n\n  * Patient with relapsing-remitting multiple sclerosis according to the McDonald 2010 criteria\n  * Disease duration of less than 5 years\n  * Patients treated or not treated with first-line disease modifying therapy\n  * Detection of at least one post-Gadolinium injection active lesion identified on the initial brain MRI (T0)\n\nExclusion Criteria:\n\n* For patients only :\n\n  • Patients with a progressive form of MS other than the early relapsing-remitting form (primary progressive or secondary progressive)\n* For Patients and Controls :\n\n  * Patients with the usual contraindications for MRI (pacemaker, agitation, metal shards, claustrophobia)\n  * Patients at risk of non-compliance to the exam: basic problems with understanding, confusion, involuntary movements, poor tolerance of prolonged supine position\n  * Patients who are unable to give their consent: problems with understanding, lack of vigilance, confusion\n  * Woman who is pregnant and breastfeeding\n  * Patients with a history of neurological or psychiatric condition\n  * Patients under guardianship or trusteeship",true,"45 Years",{"count":96,"type":20},85,[62],"The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.",[25],"2024-08-05",{"date":102,"type":39},"2024-08-06",{"date":104,"type":39},"2018-06-14",{"date":106,"type":20},"2027-02-13",{"name":108,"class":46},"Assistance Publique Hopitaux De Marseille",1]